The University of Southampton
University of Southampton Institutional Repository

The importance of long-term tolerability in achieving recovery

The importance of long-term tolerability in achieving recovery
The importance of long-term tolerability in achieving recovery
Many patients with depression require long-term treatment to provide optimal clinical outcomes. Long-term tolerability is therefore important in facilitating adherence to treatment and thereby maintaining control over depressive symptoms. While the newer selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitors (SNRls) are generally better tolerated than older treatments, such as tricyclic antidepressants and monoamine oxidase inhibitors, they can still cause nausea, headache, sleep disturbances, dry mouth, weight gain and sexual dysfunction. However, SSRIs and SNRIs differ in the extent to which they are associated with adverse events. Available data suggest that treatment of depression with escitalopram (an SSRI) may result in fewer side effects than citalopram or paroxetine (other SSRIs), or venlafaxine (an SNRI). Adverse events decrease with time during long-term escitalopram treatment, and in one study, after a 52-week escitalopram treatment, fewer than 10% of patients had withdrawn due to adverse events. Escitalopram is well tolerated during long-term treatment and appears better tolerated than some other SSRIs and venlafaxine. This improved tolerability is particularly important when selecting an antidepressant for long-term use.
selective serotonin, treatment, escitalopram 10 mg, tolerability, depression, prevention, escitalopram, venlafaxine, unipolar depression, antidepressant, adverse events, primary-care patients, ssri, dysfunction, double-blind, sexual dysfunction, day, venlafaxine xr, recurrent depression, long-term treatment, paroxetine, symptoms, antidepressants, snri, tricyclic antidepressants, placebo, citalopram, major depressive disorder, serotonin reuptake inhibitors, inhibitor discontinuation syndrome, ssris
31-37
Baldwin, D.S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Baldwin, D.S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e

Baldwin, D.S. (2006) The importance of long-term tolerability in achieving recovery. International Journal of Psychiatry in Clinical Practice, 10 (Supplement 1), 31-37. (doi:10.1080/13651500600552552).

Record type: Article

Abstract

Many patients with depression require long-term treatment to provide optimal clinical outcomes. Long-term tolerability is therefore important in facilitating adherence to treatment and thereby maintaining control over depressive symptoms. While the newer selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitors (SNRls) are generally better tolerated than older treatments, such as tricyclic antidepressants and monoamine oxidase inhibitors, they can still cause nausea, headache, sleep disturbances, dry mouth, weight gain and sexual dysfunction. However, SSRIs and SNRIs differ in the extent to which they are associated with adverse events. Available data suggest that treatment of depression with escitalopram (an SSRI) may result in fewer side effects than citalopram or paroxetine (other SSRIs), or venlafaxine (an SNRI). Adverse events decrease with time during long-term escitalopram treatment, and in one study, after a 52-week escitalopram treatment, fewer than 10% of patients had withdrawn due to adverse events. Escitalopram is well tolerated during long-term treatment and appears better tolerated than some other SSRIs and venlafaxine. This improved tolerability is particularly important when selecting an antidepressant for long-term use.

Full text not available from this repository.

More information

Published date: 2006
Keywords: selective serotonin, treatment, escitalopram 10 mg, tolerability, depression, prevention, escitalopram, venlafaxine, unipolar depression, antidepressant, adverse events, primary-care patients, ssri, dysfunction, double-blind, sexual dysfunction, day, venlafaxine xr, recurrent depression, long-term treatment, paroxetine, symptoms, antidepressants, snri, tricyclic antidepressants, placebo, citalopram, major depressive disorder, serotonin reuptake inhibitors, inhibitor discontinuation syndrome, ssris

Identifiers

Local EPrints ID: 62266
URI: https://eprints.soton.ac.uk/id/eprint/62266
PURE UUID: a40e66f6-bde9-4fb9-9d8c-4ae54605604e

Catalogue record

Date deposited: 04 Sep 2008
Last modified: 13 Mar 2019 20:27

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×